About OncoSynergy

Guiding Principles

We put patients first

We are physicians interested in durable outcomes and cures

Cancer biology is highly complex

Monotherapies will always result in resistance

Synergistic combinations are the key to durable responses

Should include a resistance inhibitor and an immunotherapy

Company Overview

The vision of OncoSynergy, a UCSF spin-out, is to radically improve outcomes for cancer patients with gravely underserved needs, starting with glioblastoma, the most common and malignant primary brain cancer.

Our intent is to develop transformative, multi-indication, platform drugs that change the standards of care, with the goal of providing durable outcomes and cures for patients. We will leverage corporate partnerships and enhanced Food and Drug Administration programs to expedite programs to market. To date, OncoSynergy has been awarded two Orphan Drug Designations by the FDA Office of Orphan Products Development including in the treatment of glioblastoma and ovarian cancer.